Mexichem Fluor S.a. De C.v.

Mexichem Amanco Holding S.a. De C.v.

Other

Timothy James Noakes

Stuart Corr

Michael Leslie Green

Alan C Outhwaite

Robert H Greene

Jonathan Jones

A pharmaceutical composition is described. The composition comprises: (i) a drug component consisting of salmeterol xinafoate and fluticasone propionate. and (ii) a propellant component at least 90 wt % of which is 1,1-difluoroethane (HFA-152a). The drug component is the sole drug component in the pharmaceutical composition.

Pharmaceutical composition

A pharmaceutical composition is described. The composition may include a drug component and a propellant component. The drug component comprises at least one pharmaceutically acceptable salt of glycopyrrolate, budesonide, and at least one long acting beta-2-agonist (LABA) selected from formoterol and the pharmaceutically acceptable salts thereof. The propellant component comprises 1,1-difluoroethane (HFA-152a).

A pharmaceutical composition is described. The composition may include a drug component and a propellant component. The drug component comprises at least one pharmaceutically acceptable salt of glycopyrrolate, beclomethasone diproprionate, and at least one long acting beta-2-agonist (LABA) selected from formoterol and the pharmaceutically acceptable salts thereof. The propellant component comprises 1,1-difluoroethane (HFA-152a).

A pharmaceutical composition is described. The composition may include a drug component and a propellant component. The drug component comprises at least one pharmaceutically acceptable salt of glycopyrrolate and at least one long acting beta-2-agonist (LABA) selected from formoterol and the pharmaceutically acceptable salts thereof. At least 90 weight % of the propellant component is 1,1-difluoroethane (HFA-152a).

A pharmaceutical composition is described. The composition comprises: (i) at least one formoterol compound selected from formoterol, pharmaceutically acceptable salts of formoterol, prodrugs of formoterol, solvates of formoterol, solvates of pharmaceutically acceptable salts of formoterol and solvates of prodrugs of formoterol; (ii) at least one corticosteroid; (iii) a surfactant component comprising at least one surfactant compound; and (iv) a propellant component comprising 1,1-difluoroethane (R-152a).

A pharmaceutical composition is described. The composition comprises: (i) a drug component comprising at least one salmeterol compound selected from salmeterol and the pharmaceutically acceptable derivatives thereof; and (ii) a propellant component comprising 1,1-difluoroethane (HFA-152a).

A pharmaceutical composition is described. The composition comprises: (i) a drug component comprising at least one indacaterol compound selected from indacaterol and the pharmaceutically acceptable derivatives thereof; and (ii) a propellant component comprising 1,1-difluoroethane (HFA-152a).

A pharmaceutical composition is described. The composition may include: (i) a drug component including at least one pharmaceutically acceptable salt of glycopyrrolate; and (ii) a propellant component including 1,1-difluoroethane (HFA-152a).

A pharmaceutical composition is described that is suitable for delivery from a pressurised container. The composition is preferably free of polar excipients and comprises: (a) a propellant component that consists essentially of 1,1-difluoroethane (R-152a); (b) a surfactant component that comprises at least one surfactant compound other than oleic acid; and (c) a drug component that consists of salbutamol sulphate. The pharmaceutical composition can be delivered using a metered dose inhaler (MDI).

Composition comprising salbutamol sulphate

A pharmaceutical composition is described. The composition comprises: (i) a drug component comprising at least one pharmaceutically acceptable salt of giycopyrrolate; and (ii) a propellant component comprising 1,1-difluoroethane (HFA-152a).

Growing community of inventors

Flintshire, United Kingdom

Timothy James Noakes